Search - tctmd.com

Displaying 501 - 520 of 576

Sort: Relevancy | Date

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News CRT 2017

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Michael O'Riordan

February 23, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Daily News

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

Michael O'Riordan

February 14, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Michael O'Riordan

January 05, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

Advertisement

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

HDL Function Improved With Olive Oil-Enriched Mediterranean Diet: PREDIMED Study

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Alirocumab to Remain On Market While Companies Clash Over Patents

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content